{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:20:32Z","timestamp":1787980832226,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"DOI":"10.7759\/cureus.115380","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:06:12Z","timestamp":1787979972000},"source":"Crossref","is-referenced-by-count":0,"title":["Opioid Toxicity Associated With Tirzepatide in a Patient on Chronic Oral Morphine"],"prefix":"10.7759","author":[{"given":"Nirosh E","family":"Mataraarachchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar D","family":"Dellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Babakhanians","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.40890","article-title":"Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity","volume":"8","author":"Li P","year":"2025","unstructured":"Li P, Varghese JS, Shah MK, Galindo RJ, Pasquel FJ, Ali MK, Shao H. Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity. JAMA Netw Open. 2025, 8:e2540890. 10.1001\/jamanetworkopen.2025.40890","journal-title":"JAMA Netw Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh RJ","year":"2024","unstructured":"Jalleh RJ, Marathe CS, Rayner CK, et al.. Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility. Endocrinology. 2024, 166:bqae155. 10.1210\/endocr\/bqae155","journal-title":"Endocrinology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh RJ","year":"2024","unstructured":"Jalleh RJ, Plummer MP, Marathe CS, et al.. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J Clin Endocrinol Metab. 2024, 110:1-15. 10.1210\/clinem\/dgae719","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","unstructured":"Zepbound (tirzepatide). https.\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70007","article-title":"GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis","volume":"45","author":"Hooper L","year":"2025","unstructured":"Hooper L, Liu S, Pai MP. GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy. 2025, 45:211-9. 10.1002\/phar.70007","journal-title":"Pharmacotherapy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky B","year":"2024","unstructured":"Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review. Drug Saf. 2024, 47:439-51. 10.1007\/s40264-023-01392-3","journal-title":"Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document","volume":"89","author":"Riley DS","year":"2017","unstructured":"Riley DS, Barber MS, Kienle GS, et al.. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017, 89:218-35. 10.1016\/j.jclinepi.2017.04.026","journal-title":"J Clin Epidemiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199407000-00013","article-title":"Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine: the influence of renal failure","volume":"81","author":"D'Honneur G","year":"1994","unstructured":"D'Honneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine: the influence of renal failure. Anesthesiology. 1994, 81:87-93. 10.1097\/00000542-199407000-00013","journal-title":"Anesthesiology"},{"key":"ref10","unstructured":"Morphine sulfate. https.\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f7e9a4b3-a2ee-4f0a-becd-6ef90867332b."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin","volume":"49","author":"Bockbrader HN","year":"2010","unstructured":"Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010, 49:661-9. 10.2165\/11536200-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70867","article-title":"Association of GLP-1 receptor agonist use with safety outcomes in individuals with opioid use disorder: a target trial emulation","author":"Hussain T","year":"2026","unstructured":"Hussain T, Al Faysal J, Kotecha P, et al.. Association of GLP-1 receptor agonist use with safety outcomes in individuals with opioid use disorder: a target trial emulation. Diabetes Obes Metab. 2026, 10.1111\/dom.70867","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S138698","article-title":"Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management","volume":"10","author":"Feng XQ","year":"2017","unstructured":"Feng XQ, Zhu LL, Zhou Q. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J Pain Res. 2017, 10:1225-39. 10.2147\/JPR.S138698","journal-title":"J Pain Res"},{"key":"ref15","unstructured":"FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. https.\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-recommends-health-care-professionals-discuss-naloxone-all-pati...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/506308-opioid-toxicity-associated-with-tirzepatide-in-a-patient-on-chronic-oral-morphine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:06:14Z","timestamp":1787979974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/506308-opioid-toxicity-associated-with-tirzepatide-in-a-patient-on-chronic-oral-morphine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.115380","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}